AGM Statement

| Source: Novo Nordisk A/S Novo Nordisk A/S

At the Annual General Meeting of Novo Nordisk A/S today, the shareholders made the following resolutions:
 
  •          Adoption of the audited Annual Report 2004, including approval of the remuneration of the Board of Directors.


    •  
  •          Resolution to distribute the profit according to the adopted Annual Report 2004. The dividend will be DKK 4.80 per share of DKK 2, an increase of 9% compared with 2003.
    •  
     
  •          Board members elected by the Annual General Meeting: Re-election of Mads Øvlisen, Sten Scheibye, Kurt Briner, Niels Jacobsen, Kurt Anker Nielsen and Jørgen Wedel and election of Göran A Ando and Henrik Gürtler.


    •  
  •          Re-election of the auditor, PricewaterhouseCoopers.
    •  
     
  •          Authorisation to the Board of Directors, until the next Annual General Meeting, to allow Novo Nordisk A/S to acquire own shares of up to 10% of the share capital and at the price quoted on the date of purchase with a deviation of up to 10%, cf Article 48 of the Danish Companies Act.
    •  
    The Board of Directors
     
    Accordingly the Board of Directors of Novo Nordisk A/S comprises:
     
  •        Mads Øvlisen
  •        Sten Scheibye
  •        Göran A Ando
  •        Kurt Briner
  •        Henrik Gürtler
  •       Johnny Henriksen (employee representative)
  •        Niels Jacobsen
  •       Anne Marie Kverneland (employee representative)
  •        Kurt Anker Nielsen
  •        Stig Strøbæk (employee representative)
  •        Jørgen Wedel
    •  

    For information on the board members, please refer to novonordisk.com.
     
    At a board meeting immediately after the Annual General Meeting, the Board of Directors constituted itself with Mads Øvlisen as chairman and Sten Scheibye as vice chairman.
     
    The Board of Directors elected Kurt Anker Nielsen, Niels Jacobsen and Jørgen Wedel as members of the Audit Committee with Kurt Anker Nielsen as chairman. Kurt Anker Nielsen and Niels Jacobsen were designated by the Board of Directors as Audit Committee Financial Experts.
     
    Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 20,250 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
     
    For further information please contact:
     
     
    Stock Exchange Announcement No 13 /2005